HSPA8 and cancer: Apart from regulating the Wnt/β‐catenin pathway, HSPA8 may directly upregulate the MAPK cascade to promote CRC progression and desensitize cancer cells to BRAF V600E inhibitors, which is consistent with previous reports.[36] Furthermore, HSPA8 inhibitors show synergistic effects with BRAF V600E inhibitors in CRC cells, indicating their potential for clinical use.